SCHEMBL624701

SCHEMBL624701

Cc1noc(-c2ccccc2)c1C(=O)N1CCN(c2cc(OCC(C)C)ncn2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 7/20 0.43
TSHR P16473 3/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 4/20 0.40
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
ALDH1A1 P00352 7/20 0.40
HSD17B10 Q99714 4/20 0.40
USP2 O75604 4/20 0.40
HIF1A Q16665 1/20 0.40
HPGD P15428 3/20 0.39
MAPK1 P28482 2/20 0.39
CYP2C19 P33261 1/20 0.39
GAA P10253 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
HTT P42858 1/20 0.38
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623264 0.86 SMN1; SMN2 (0.57) SMN1; SMN2TSHRKMT2AKDM4EALDH1A1
SCHEMBL624208 0.83 SCD5 (0.57) MAPTSMN1; SMN2TSHRMEN1KMT2A
SCHEMBL624222 0.81 DGAT1 (0.42) MAPTSMN1; SMN2TSHRMEN1KMT2A
SCHEMBL623692 0.79 HRH4 (0.47) SMN1; SMN2TSHRKDM4EALDH1A1HSD17B10
SCHEMBL623195 0.78 MGLL (0.41) MAPTSMN1; SMN2TSHRMEN1KMT2A
SCHEMBL624275 0.77 KDM4E (0.40) MAPTSMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL624199 0.77 CYP1A2 (0.48) KDM4EALDH1A1HPGDCYP2C19
SCHEMBL623270 0.77 CYP1A2 (0.48) CYP2C19
SCHEMBL623783 0.76 PTGDR2 (0.43)
SCHEMBL622833 0.75 LOXL2 (0.43) SMN1; SMN2MEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G MAPT 3432/4885SMN1; SMN2 598/4885TSHR 1643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.